Abstract: Gastric cancer is one of the most common cancers all over the world. Surgery is the main treatment for gastric cancer. Advanced gastric cancer presents with a high recurrence rate At present, the survival benefit of postoperative chemotherapy is not satisfactory. In order to increase the number of patients for potential curative surgery, researchers have begun to pay more attention on neoadjuvant chemotherapy. Some new drugs (Docetaxel) and new chemotherapy regimens (FOLFOX) have been developed recently. We reviewed the current status of neoadjuvant chemotherapy for advanced gastric cancer.